406 related articles for article (PubMed ID: 32665011)
1. The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Wang Y; Sun Q; Mu N; Sun X; Wang Y; Fan S; Su L; Liu X
Cell Commun Signal; 2020 Jul; 18(1):112. PubMed ID: 32665011
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
3. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitination and Stabilization of PD-L1 by CSN5.
Lim SO; Li CW; Xia W; Cha JH; Chan LC; Wu Y; Chang SS; Lin WC; Hsu JM; Hsu YH; Kim T; Chang WC; Hsu JL; Yamaguchi H; Ding Q; Wang Y; Yang Y; Chen CH; Sahin AA; Yu D; Hortobagyi GN; Hung MC
Cancer Cell; 2016 Dec; 30(6):925-939. PubMed ID: 27866850
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
Li J; Li Y; Wang B; Ma Y; Chen P
Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
[TBL] [Abstract][Full Text] [Related]
7. PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1.
Ma Y; Xia P; Wang Z; Xu J; Zhang L; Jiang Y
Neoplasia; 2021 Sep; 23(9):912-928. PubMed ID: 34325342
[TBL] [Abstract][Full Text] [Related]
8. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
9. USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.
Pan J; Qiao Y; Chen C; Zang H; Zhang X; Qi F; Chang C; Yang F; Sun M; Lin S; Tang Q; Li L; Wang M; Wu M; Liu Y; Lai C; Chen J; Chen G
Cell Death Dis; 2021 Nov; 12(11):1051. PubMed ID: 34741014
[TBL] [Abstract][Full Text] [Related]
10. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
11. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity
Liu Y; Liu X; Zhang N; Yin M; Dong J; Zeng Q; Mao G; Song D; Liu L; Deng H
Acta Pharm Sin B; 2020 Dec; 10(12):2299-2312. PubMed ID: 33354502
[TBL] [Abstract][Full Text] [Related]
12. USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity.
Huang X; Zhang Q; Lou Y; Wang J; Zhao X; Wang L; Zhang X; Li S; Zhao Y; Chen Q; Liang T; Bai X
Cancer Immunol Res; 2019 Oct; 7(10):1580-1590. PubMed ID: 31399419
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
14. A Novel Link between Inflammation and Cancer.
Grinberg-Bleyer Y; Ghosh S
Cancer Cell; 2016 Dec; 30(6):829-830. PubMed ID: 27960080
[TBL] [Abstract][Full Text] [Related]
15. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
Wang Z; Kang W; Li O; Qi F; Wang J; You Y; He P; Suo Z; Zheng Y; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):694-707. PubMed ID: 33777676
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
18. Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract][Full Text] [Related]
19. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
[TBL] [Abstract][Full Text] [Related]
20. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
